# Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

> **NCT02333188** · PHASE1 · COMPLETED · sponsor: **University of Chicago** · enrollment: 50 (actual)

## Conditions studied

- Adenocarcinoma of Unknown Primary
- Adult Cholangiocarcinoma
- Gallbladder Carcinoma
- Gastric Adenocarcinoma
- Malignant Gastrointestinal Neoplasm
- Metastatic Pancreatic Adenocarcinoma
- Pancreatic Adenocarcinoma
- Stage III Ampulla of Vater Cancer
- Stage III Pancreatic Cancer
- Stage IIIA Gallbladder Cancer
- Stage IIIA Gastric Cancer
- Stage IIIB Gallbladder Cancer
- Stage IIIB Gastric Cancer
- Stage IV Ampulla of Vater Cancer
- Stage IV Gallbladder Cancer
- Stage IV Gastric Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** Paclitaxel Albumin-Stabilized Nanoparticle Formulation
- **DRUG:** Leucovorin Calcium
- **DRUG:** Irinotecan Hydrochloride
- **DRUG:** Fluorouracil
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02333188
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02333188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02333188, "Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02333188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*